See also this year's filing and all EDGAR filings for this company.
PDF Report 0001503802_2014_Karyopharm_Therapeutics_Inc.pdf
Logs
| warning | The EntityCommonStockSharesOutstanding does not exist | industry.us_generic | {} |
| info | NetIncome node detected by revenue/expenses heuristic | input.sec.calculation_linkbase.edgar_model_mapping | {'net_inc_node': 'OperatingIncomeLoss'} |
Graph
Absolute values for 0001503802, Karyopharm Therapeutics Inc
| xvar | xval | |
|---|---|---|
| 0 | AssetsCurrent | 157,956,000 |
| 1 | IntangibleAssetsNetIncludingGoodwill | 0 |
| 2 | PropertyPlantAndEquipmentNet | 240,000 |
| 3 | remainder_Assets | 30,000 |
| 4 | LiabilitiesCurrent | 3,292,000 |
| 5 | LiabilitiesNoncurrent | 0 |
| 6 | remainder_Liabilities | 0 |
| 7 | CostOfGoodsAndServicesSold | 0 |
| 8 | SellingGeneralAndAdministrativeExpense | 5,885,000 |
| 9 | ResearchAndDevelopmentExpense | 28,452,000 |
| 10 | remainder_Expenses | 0 |
| 11 | remainder_Revenues | 387,000 |
| 12 | remainder_NetIncome | 0 |
| 13 | remainder_ComprehensiveNetIncome | 0 |
| yvar | yval | |
|---|---|---|
| 0 | Assets | 158,226,000 |
| 1 | Liabilities | 3,292,000 |
| 2 | Expenses | 34,337,000 |
| 3 | Revenues | 387,000 |
| 4 | StockholdersEquity | 154,934,000 |
| 5 | NetIncome | -33,950,000 |
| 6 | ComprehensiveNetIncome | -33,950,000 |
| 7 | BaseVar | 98,121,000 |
| 8 | EconomicCapitalRatiobeforeLimitedLiability | 3.76 |
| 9 | EconomicCapitalRatio | 4.22 |
Edgar->Model Mapping
Feature Distribution
